Showing 121 to 132 of 151 results
Trump's Post-Election Press Conference: Healthcare, Tech, and Foreign Policy in Focus
President-elect Trump, in his first post-election press conference, addressed vaccine policy, pharmaceutical costs, potential appointments, and foreign policy, revealing potential shifts in healthcare, technology, and international relations.
Trump's Post-Election Press Conference: Healthcare, Tech, and Foreign Policy in Focus
President-elect Trump, in his first post-election press conference, addressed vaccine policy, pharmaceutical costs, potential appointments, and foreign policy, revealing potential shifts in healthcare, technology, and international relations.
Progress
48% Bias Score
Morgan Stanley's 2025 Market Outlook: Opportunities and Risks
Morgan Stanley's 2025 market outlook highlights "diabesity" treatments, Edge AI, and Canadian rail stocks as investment opportunities, while Wells Fargo identifies inflation, high valuations, and geopolitical risks as potential downsides for the S&P 500, which it forecasts to reach 7007.
Morgan Stanley's 2025 Market Outlook: Opportunities and Risks
Morgan Stanley's 2025 market outlook highlights "diabesity" treatments, Edge AI, and Canadian rail stocks as investment opportunities, while Wells Fargo identifies inflation, high valuations, and geopolitical risks as potential downsides for the S&P 500, which it forecasts to reach 7007.
Progress
40% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Progress
40% Bias Score
Almirall Celebrates 80 Years, Projects Growth with New Dermatology Drug
Founded 80 years ago in Barcelona, the family-owned Almirall pharmaceutical company, specializing in dermatology, anticipates significant growth with its new drug, Ebglyss, projecting €450 million in sales, while its Ilumetri drug shows 25% yearly growth.
Almirall Celebrates 80 Years, Projects Growth with New Dermatology Drug
Founded 80 years ago in Barcelona, the family-owned Almirall pharmaceutical company, specializing in dermatology, anticipates significant growth with its new drug, Ebglyss, projecting €450 million in sales, while its Ilumetri drug shows 25% yearly growth.
Progress
56% Bias Score
Astellas to Launch Innovative Cancer Treatments in China Amidst Growing Market
Astellas, a multinational pharmaceutical company, is bringing two innovative cancer treatments to China, capitalizing on the country's massive consumer base, strengthened IP protection, and improved innovation climate; China's elderly population exceeded 20% in 2022.
Astellas to Launch Innovative Cancer Treatments in China Amidst Growing Market
Astellas, a multinational pharmaceutical company, is bringing two innovative cancer treatments to China, capitalizing on the country's massive consumer base, strengthened IP protection, and improved innovation climate; China's elderly population exceeded 20% in 2022.
Progress
36% Bias Score
Egypt Partially Pays $120M in Pharmaceutical Arrears, Addressing Drug Shortages
The Egyptian government disbursed 4 billion Egyptian pounds ($80.2 million) to pharmaceutical companies, addressing 6 billion pounds ($120.5 million) in arrears, alleviating drug shortages caused by currency devaluation and import cost increases; additional payments totaling 6 billion pounds ($120.3...
Egypt Partially Pays $120M in Pharmaceutical Arrears, Addressing Drug Shortages
The Egyptian government disbursed 4 billion Egyptian pounds ($80.2 million) to pharmaceutical companies, addressing 6 billion pounds ($120.5 million) in arrears, alleviating drug shortages caused by currency devaluation and import cost increases; additional payments totaling 6 billion pounds ($120.3...
Progress
32% Bias Score
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Progress
44% Bias Score
Mexico Launches Large-Scale Medicine Purchase to Combat Shortages
The Mexican government announced a two-year, 135 billion-peso bulk purchase of medicines to address chronic shortages, involving direct negotiations with pharmaceutical companies, digital inventory management, and adjustments to distribution.
Mexico Launches Large-Scale Medicine Purchase to Combat Shortages
The Mexican government announced a two-year, 135 billion-peso bulk purchase of medicines to address chronic shortages, involving direct negotiations with pharmaceutical companies, digital inventory management, and adjustments to distribution.
Progress
40% Bias Score
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Progress
52% Bias Score
VersaBank Stock Soars on U.S. Expansion
VersaBank's stock price has more than doubled in the past year, reaching near all-time highs, driven by its US$14-million acquisition of Stearns Bank and expansion into the U.S. market with its receivables purchase program, despite lower-than-expected Q4 earnings due to deal costs.
VersaBank Stock Soars on U.S. Expansion
VersaBank's stock price has more than doubled in the past year, reaching near all-time highs, driven by its US$14-million acquisition of Stearns Bank and expansion into the U.S. market with its receivables purchase program, despite lower-than-expected Q4 earnings due to deal costs.
Progress
24% Bias Score
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Pfizer Stock Plunges 50% Amidst Falling Sales and Vaccine Concerns
Pfizer stock is down 50% since early 2022 to $26, driven by a 42% fall in 2023 sales to $58.5 billion following the Covid-19 pandemic and concerns over new leadership's stance on vaccines, despite efforts to cut costs and develop new drugs.
Progress
40% Bias Score
France's Healthcare Cost-Cutting Measures Face Backlash
The French government's new measures to curb healthcare spending, including reducing reimbursements for consultations and medications, spark criticism from various stakeholders who express concerns over the potential impact on healthcare access and affordability.
France's Healthcare Cost-Cutting Measures Face Backlash
The French government's new measures to curb healthcare spending, including reducing reimbursements for consultations and medications, spark criticism from various stakeholders who express concerns over the potential impact on healthcare access and affordability.
Progress
40% Bias Score
Showing 121 to 132 of 151 results